Re-irradiationCalculator
EQD2-based D0.1cc point-dose budgeting for re-irradiation — University of Michigan (time-forgiveness) & No-Forgiveness (Safer / Borderline) methods.
Reference data & logic ported from “Re-irradiation Spreadsheet w EQD2 calc JMR 2.12”. For clinical decision support only — verify independently.
▸How to use this calculator
Re-irradiation cases are among the most difficult to plan and peer review. Image fusions between courses must be inspected directly — they cannot always be trusted — and the dose contributions from both courses must be evaluated together. Above all, these cases require clinical judgment; no calculator replaces it.
To identify the relevant organs at risk, focus on the dose cloud around the new PTV (e.g., a ReRT PTV_Ev10/20 structure, or a 1–2 cm ring around the new PTV). Re-irradiation is often highly conformal, and the high-dose cloud is typically what drives toxicity. For mobile structures such as small bowel, cumulative dose estimates for individual loops may be impossible because loops cannot be reliably registered between courses; point-based estimation may be required.
Re-irradiation is an area of active development. For further information, refer to the numerous publications of the ESTRO Reirradiation Focus Group and the Reirradiation Collaborative Group (ReCOG).
Prior courses & organ doses
| Organ at risk | Prior course 1 # fx time unit | |
|---|---|---|
Each course column shares its # fractions and time-since across all organs (as in the spreadsheet). Leave a dose blank if that organ was not exposed in that course.
Results — max new-plan physical D0.1cc (cGy)
| Organ | Prior cum. EQD2 No-Forgive (cGy) | Prior cum. EQD2 Michigan (cGy) | Michigan new D0.1cc | NF — Safer new D0.1cc | NF — Borderline new D0.1cc |
|---|---|---|---|---|---|
| — | select an organ | ||||
* Kidneys, Liver, Lungs are mean-dose organs — no point-dose lifetime limit is defined (shown N/A). “OTHER” has no α/β, so EQD2/Michigan cannot be computed.
The no-forgiveness “Safer” and “Borderline” metrics shown in this tool are a sample selected from metrics at www.cancerretreatment.org.
▸Advanced — edit reference tolerances & α/β
Edits apply immediately to the results above. Discount schedule is fixed to the 2025 Michigan values in this version.
| Organ | α/β (NF) | α/β (Mich) | Michigan lifetime EQD2 (cGy) | NF Safer EQD2 (cGy) | NF Borderline EQD2 (cGy) | Discount schedule (yr : % forgiven) |
|---|---|---|---|---|---|---|
| No organs selected — add organs above, or check “Show All”. | ||||||
▸Advanced — edit time-forgiveness (default Michigan)
Michigan forgiveness (% of prior EQD2 forgiven) is derived from each course's time-since entry above. A blank time is treated as 0% forgiveness. Check “Custom time forgiveness” to override any value (0–100%); if checked, customizable time-forgiveness areas are added to Results and Advanced section. N/A means there is no specific time-forgiveness guidance from Michigan for that OAR; you may still enter a custom value.
| Organ | Prior course 1 Michigan forgiveness |
|---|---|
| Select organs in “Prior courses & organ doses” above to see their forgiveness values. | |
Method. EQD2 = D · (d + α/β) / (2 + α/β), with d = D/n, applied only when d > 2 Gy (otherwise physical = EQD2). Michigan multiplies each prior course's EQD2 by (1 − discount), where the discount (fraction forgiven) increases with time since that course. Cumulative prior EQD2 is subtracted from the organ's lifetime/tolerance EQD2; the remainder is back-converted to a physical dose for the new plan's fraction count. If a course's time-since entry is blank, 0% forgiveness is applied (the full prior EQD2 is counted). Custom time-forgiveness values, when enabled, replace the Michigan schedule for that organ and course.
Disclaimer. This calculator is a decision-support aid, not a substitute for clinical judgment or independent verification. Confirm all values, α/β assumptions, and institutional tolerances before use in patient care.
Credits. Jeff Ryckman, MD, MSMP. Special thanks to Alf Siochi, PhD, DABR, and Matt Culbert, MD.